PharmaRadar360

PharmaRadar360

Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

38,271 stories, page 236 of 638

Advanced search
🌍discoverynews.google.comTier 3 · Aggregated media

Q&A: Why Sponsors Are Turning to Mixed FSP/FSO Models

PharmTech.comOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

10,000-plus in South Korea are estimated to have a rare retinal disease; Kiora licenses KIO-301

Stock TitanOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation

TMX NewsfileOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Nonprofit Cville BioHub working to develop local talent for AstraZeneca and the area’s growing biotech industry

Cville Right NowOriginal source
🌍discoverynews.google.comTier 2 · Trade media

Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial

STATOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Cancer vaccine from Moderna, Merck shows promise in late-stage trial; both stocks soar

CNBCOriginal source
🌍discoverynews.google.comTier 2 · Trade media

Merck, Moderna’s personalized cancer vaccine slows recurrence in phase 3, setting up approval push

Fierce BiotechOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Merck and Moderna report first positive Phase 3 readout for an investigational mRNA therapy

Stock TitanOriginal source
🌍discoverynews.google.comTier 2 · Trade media

Merck, Moderna declare Phase 3 success for personalized mRNA cancer vaccine

Endpoints NewsOriginal source
🌍discoverynews.google.comTier 2 · Trade media

Trump expected to nominate Heidi Overton as new FDA commissioner

pharmaceutical-technology.comOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Meeder Asset Management Inc. Makes New Investment in West Pharmaceutical Services, Inc. $WST

MarketBeatOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Operation TrialBlazer: How the FDA’s Expedited IND Pilot Program Aims to Halve Early Clinical Timelines

geneonline.comOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

AI integration in pharmaceutical processes remains focused on high-impact functions

PharmaLiveOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Three years into the UPC: The Hague takes the lead in pharmaceutical patent litigation

FreshfieldsOriginal source
🇺🇰Researchmedsci.ox.ac.ukTier 2 · Direct publisher

Study of 3,400 children links London's Ultra Low Emission Zone with improved lung growth

Oxford MedicineOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

symbol__ Stock Quote Price and Forecast

CNNOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Legend Biotech (LEGN) Turns Profitable In Q2, Is The Stock Cheap?

simplywall.stOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Neoimmunetech licenses NT-I7 rights to U.S. biotech in $260 million deal - CHOSUNBIZ

ChosunbizOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Pune: FDA Suspends Hotel Chul Muttons Licence; Banned Products Worth ₹10 Lakh Seized In 4-Day Drive

Free Press JournalOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

BIOG Keeps Its Focus On Small-cap Biotech And M&A Potential

DirectorsTalk InterviewsOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Pharma in hackers' crosshairs as Amgen breach moves to courts

The Pharma LetterOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Dash Bio banks $30 million to automate development bottleneck

The Pharma LetterOriginal source
🌍Regulatorynafdac.gov.ngTier 1 · Regulatory source

Public Alert No. 043/2026-NAFDAC Places Products Marketed by Mofus Nigeria Ltd on Watchlist Pending Regulatory Investigation

NAFDAC NigeriaOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation

SahmOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

3 Japanese Stocks Screening Cheap on Cash Flow Right Now

simplywall.stOriginal source
🇺🇰Regulatorygov.ukTier 1 · Regulatory source

UK Clinical Research Delivery key performance indicators: data to July 2026

Report bringing together data on the delivery of globally competitive clinical research through the...

UK Department of Health and Social CareOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Quantum BioPharma Stock Slides as Bearish Momentum, Funding Risk and Biotech Volatility Pressure CN:QNTM

kalkine.caOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Nobel laureate Baker's GenBio AI unveils whole-cell simulator

The Pharma LetterOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Britain's pricing reset: did it work?

The Pharma LetterOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Pace appoints Andy Fenny as President of Pace Life Sciences

Manufacturing ChemistOriginal source
🌍Regulatorynafdac.gov.ngTier 1 · Regulatory source

Public Alert No. 042/2026-Alert on the Seizure of Suspected Substandard and Falsified BPPL Artemether/Lumefantrine 80mg/480mg

NAFDAC NigeriaOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Does FDA-Backed Mpox mRNA Trial and AstraZeneca Tie-Up Recast the Bull Case For CSPC (SEHK:1093)?

simplywall.stOriginal source
🌍Regulatorynafdac.gov.ngTier 1 · Regulatory source

Public Alert No. 041/2026 – Alert on Suspected Counterfeit ORACIRE+ Toothpaste

NAFDAC NigeriaOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

GSA Capital Partners LLP Invests $944,000 in BioMarin Pharmaceutical Inc. $BMRN

MarketBeatOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Bombay HC vs Tukaram Munde: Pune sweet shop shut; court imposes FDA 5 lakh fine for torturing citizens; Munde fights back

IBTimes IndiaOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

ETFs Investing in Zeria Pharmaceutical Co., Ltd. Stocks

TradingViewOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Fadnavis backs Mundhe, says FDA's crackdown on food safety will continue

Business StandardOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Scancell Shares Rise as MHRA Clears Phase 3 Melanoma Trial

AskTradersOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Eyes on Pharma’s Psychedelic Pipeline: $5B+ Investments, Phase 3 Trials & Top Drug Developers

geneonline.comOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

When Your CRO Gets Acquired Mid-Study, Your Site Feels It First

The Clinical Trial VanguardOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Upadacitinib’s Phase 3 Vitiligo Data Just Redrew the Regulatory Map for JAK Inhibitors in Dermatology

The Clinical Trial VanguardOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

ETFs Investing in HUBEI JUMPCAN PHARMACEUTICAL CO., LTD Class A Stocks

TradingViewOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Inha University opens semiconductor and biotech education building to train industry-ready graduates

mbiz.heraldcorp.comOriginal source
🇩🇪Researchuni-heidelberg.deTier 2 · Direct publisher

Light-Based 3D Printing: Innovative “Ink” Enables a Closed-Loop Material Cycle

Heidelberg UniversityOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Bank of America Corp DE Has $21.93 Million Stock Position in Ultragenyx Pharmaceutical Inc. $RARE

MarketBeatOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

YNS Skin Care Advances Physician-Formulated Skincare With PharmD Expertise and Facial Cosmetic Surgery Insight

StreetInsiderOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Biovica receives new extensive Pharma Services work order from existing customer

TradingViewOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

K'taka FDA seizes spurious drugs worth Rs 4.91 crore

English VarthabharatiOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Karnataka FDA Seizes Spurious Drugs Worth Rs 4.91 Crore

Deccan ChronicleOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Duopharma Biotech maintains healthy profit growth in H1FY2026

markets.businessinsider.comOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Amylyx Avexitide Meets Primary Endpoint in Phase 3 Post-Bariatric Hypoglycemia Trial

The Clinical Trial VanguardOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Amylyx’s avexitide meets Phase 3 endpoints in post-bariatric hypoglycemia trial

The Clinical Trial VanguardOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

What This Top Biotech Fund Is Buying Now

Barron'sOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Why Oncolytics Biotech Just Cleared A Hurdle That Stalls Most Cancer Trials

Yahoo FinanceOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Maharashtra FDA Cracks Down on Mumbai Eateries; Karnataka Busts ₹5 Crore Fake Drug Racket| News18

News18Original source
🌍discoverynews.google.comTier 3 · Aggregated media

Ono Pharmaceutical : OPDIVO® Intravenous Infusion Approved in Taiwan for the Treatment of Resectable Non-Small Cell Lung Cancer with Neoadjuvant OPDIVO in Combination with Chemotherapy Followed by Surgery and Adjuvant Single-Agent OPDIVO

marketscreener.comOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Biotech firm surges after US approval of new cancer therapy

Aju PressOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

REG - RTW Biotech Opp. - BioMarin to acquire Alesta Therapeutics

TradingViewOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Price to sales forward of Gulf Pharmaceutical Industries – ADX:JULPHAR

TradingViewOriginal source
🌍Industryeikontx.comTier 1 · Company source

Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald

Eikon TherapeuticsOriginal source